Phase II trial of adjuvant mFOLFOX6 after metastasectomy for lung metastasis of colorectal cancer - Phase II trial of adjuvant mFOLFOX6 after metastasectomy for lung metastasis of colorectal cancer

West Japan Oncology Group0 个研究点目标入组 100 人开始时间: 2011年6月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Adjuvant FU was terminated because of ADR. 2)Multiple cancer patient (within 5 years) 3)Transfusion or blood product or growth factor such as G-CSF less than 14 days prior to entry. 4)Have following severe complications. i)Bowel obstruction ii)Uncontrolable heart disease iii)Severe pulmonary fibrosis, interstitial lung disease, COPD iv)Uncontrolable hypertension v)Uncontrolable diabetes vi)Active peptic ulcer vii)Uncontrolable diarrhea viii)bleeding diathesis ix)HIV infection x)Active infectious disease 5)Systemic and continuous steroids medication. 6)Severe peripheral neuropathy. 7)History of the serious hypersensitivity for drugs 8)Hepatitis B virus infection 9)Clinically significant mental or psychological disease. 10)Not pregnant 11)Patient who is taking flucytosine, phenytoin or warfarin potassium continuously. 12)Other conditions not suitable for this study.

发起方